Skip to main content

Bank of America Securities Remains a Buy on Supernus Pharmaceuticals (SUPN)

Tipranks - Tipranks - Wed Jan 21, 5:52AM CST

Bank of America Securities analyst Pavan Patel reiterated a Buy rating on Supernus Pharmaceuticals today and set a price target of $65.00.

Claim 50% Off TipRanks Premium

According to TipRanks, Patel is a 2-star analyst with an average return of 2.2% and a 60.00% success rate. Patel covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Catalyst Pharma, and Amphastar Pharmaceuticals.

In addition to Bank of America Securities, Supernus Pharmaceuticals also received a Buy from Piper Sandler’s David Amsellem in a report issued on January 9. However, on January 15, TipRanks – Anthropic reiterated a Hold rating on Supernus Pharmaceuticals (NASDAQ: SUPN).

See Insiders’ Hot Stocks on TipRanks >>

Based on Supernus Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $192.1 million and a GAAP net loss of $45.12 million. In comparison, last year the company earned a revenue of $175.69 million and had a net profit of $38.5 million

Read More on SUPN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).